Silence Therapeutics PLC Net Income
| SLN Stock | USD 4.75 0.23 5.09% |
As of the 8th of February, Silence Therapeutics has the Risk Adjusted Performance of (0.07), coefficient of variation of (1,008), and Variance of 17.4. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Silence Therapeutics PLC, as well as the relationship between them.
Silence Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 4.8282 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -32.6 M | -30.9 M | |
| Net Loss | -40.8 M | -42.8 M | |
| Net Loss | -36.4 M | -38.3 M | |
| Net Loss | (2.65) | (2.78) | |
| Net Income Per E B T | 1.17 | 0.98 |
Silence | Net Income | Build AI portfolio with Silence Stock |
Evaluating Silence Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Silence Therapeutics PLC's fundamental strength.
Latest Silence Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Silence Therapeutics PLC over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Silence Therapeutics PLC financial statement analysis. It represents the amount of money remaining after all of Silence Therapeutics PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Silence Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Silence Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (36.19 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Silence Net Income Regression Statistics
| Arithmetic Mean | (23,415,606) | |
| Coefficient Of Variation | (73.06) | |
| Mean Deviation | 15,216,877 | |
| Median | (19,582,000) | |
| Standard Deviation | 17,107,157 | |
| Sample Variance | 292.7T | |
| Range | 49.5M | |
| R-Value | (0.84) | |
| Mean Square Error | 94.1T | |
| R-Squared | 0.70 | |
| Significance | 0.000029 | |
| Slope | (2,831,229) | |
| Total Sum of Squares | 4682.5T |
Silence Net Income History
Other Fundumenentals of Silence Therapeutics PLC
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Silence Therapeutics Net Income component correlations
Silence Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Silence Therapeutics is extremely important. It helps to project a fair market value of Silence Stock properly, considering its historical fundamentals such as Net Income. Since Silence Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Silence Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Silence Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Silence diversify its offerings? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Silence Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Silence Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Silence Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Silence Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Silence Therapeutics.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Silence Therapeutics on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Silence Therapeutics PLC or generate 0.0% return on investment in Silence Therapeutics over 90 days. Silence Therapeutics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, Lipocine, and SeaStar Medical. Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid th... More
Silence Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Silence Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Silence Therapeutics PLC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 23.8 | |||
| Value At Risk | (5.89) | |||
| Potential Upside | 6.88 |
Silence Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Silence Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Silence Therapeutics' standard deviation. In reality, there are many statistical measures that can use Silence Therapeutics historical prices to predict the future Silence Therapeutics' volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (0.82) |
Silence Therapeutics February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.81) | |||
| Mean Deviation | 3.04 | |||
| Coefficient Of Variation | (1,008) | |||
| Standard Deviation | 4.17 | |||
| Variance | 17.4 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (0.82) | |||
| Maximum Drawdown | 23.8 | |||
| Value At Risk | (5.89) | |||
| Potential Upside | 6.88 | |||
| Skewness | 0.2566 | |||
| Kurtosis | 1.47 |
Silence Therapeutics PLC Backtested Returns
Silence Therapeutics PLC owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0899, which indicates the firm had a -0.0899 % return per unit of risk over the last 3 months. Silence Therapeutics PLC exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Silence Therapeutics' Variance of 17.4, risk adjusted performance of (0.07), and Coefficient Of Variation of (1,008) to confirm the risk estimate we provide. The entity has a beta of 0.52, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Silence Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Silence Therapeutics is expected to be smaller as well. At this point, Silence Therapeutics PLC has a negative expected return of -0.38%. Please make sure to validate Silence Therapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Silence Therapeutics PLC performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.51 |
Modest predictability
Silence Therapeutics PLC has modest predictability. Overlapping area represents the amount of predictability between Silence Therapeutics time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Silence Therapeutics PLC price movement. The serial correlation of 0.51 indicates that about 51.0% of current Silence Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | 0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 0.3 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Silence Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Silence Therapeutics PLC reported net income of (36.19 Million). This is 110.6% lower than that of the Biotechnology sector and 151.67% lower than that of the Health Care industry. The net income for all United States stocks is 106.34% higher than that of the company.
Silence Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Silence Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Silence Therapeutics could also be used in its relative valuation, which is a method of valuing Silence Therapeutics by comparing valuation metrics of similar companies.Silence Therapeutics is currently under evaluation in net income category among its peers.
Silence Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Silence Therapeutics from analyzing Silence Therapeutics' financial statements. These drivers represent accounts that assess Silence Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Silence Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 523.4M | 135.3M | 168.9M | 106.1M | 95.5M | 98.0M | |
| Enterprise Value | 450.0M | 80.9M | 100.4M | (15.1M) | (13.6M) | (12.9M) |
Silence Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Silence Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Silence Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Silence Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Silence Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Silence Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Silence Therapeutics' value.| Shares | Boothbay Fund Management, Llc | 2025-06-30 | 252.4 K | Ubs Group Ag | 2025-06-30 | 228.5 K | Millennium Management Llc | 2025-06-30 | 198.6 K | M28 Capital Management Lp | 2025-06-30 | 185.1 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 175.9 K | Hsbc Holdings Plc | 2025-06-30 | 172.8 K | Blackrock Inc | 2025-06-30 | 168.2 K | Bank Of Montreal | 2025-06-30 | 145.8 K | Bmo Capital Markets Corp. | 2025-06-30 | 145.8 K | Tcg Crossover Management, Llc | 2025-06-30 | 3 M | Siren, L.l.c. | 2025-06-30 | 2.9 M |
Silence Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (2.50) % | ||||
| Operating Margin | (148.81) % | ||||
| Current Valuation | 124.71 M | ||||
| Shares Outstanding | 47.23 M | ||||
| Shares Owned By Insiders | 24.37 % | ||||
| Shares Owned By Institutions | 41.99 % | ||||
| Number Of Shares Shorted | 1.33 M | ||||
| Price To Book | 3.02 X | ||||
| Price To Sales | 8.69 X | ||||
| Revenue | 43.26 M | ||||
| Gross Profit | 23.59 M | ||||
| EBITDA | (48.99 M) | ||||
| Net Income | (36.19 M) | ||||
| Cash And Equivalents | 51.56 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 117 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.76 X | ||||
| Book Value Per Share | 1.57 X | ||||
| Cash Flow From Operations | (67.64 M) | ||||
| Short Ratio | 3.43 X | ||||
| Earnings Per Share | (1.35) X | ||||
| Target Price | 33.8 | ||||
| Number Of Employees | 116 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 326.86 M | ||||
| Total Asset | 202.63 M | ||||
| Retained Earnings | (474.04 M) | ||||
| Working Capital | 170.54 M | ||||
| Net Asset | 202.63 M |
About Silence Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Silence Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Silence Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Silence Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Silence Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Silence Stock
Moving against Silence Stock
| 0.63 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.6 | ENGN | enGene Holdings Common | PairCorr |
| 0.55 | DSGN | Design Therapeutics | PairCorr |
| 0.38 | 63E | ONWARD MEDICAL BV | PairCorr |
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Will Biotechnology sector continue expanding? Could Silence diversify its offerings? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Silence Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Silence Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.